• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Calprotectin in Chronic Rhinosinusitis Eosinophil Extracellular Traps
Conclusions: Calprotectin, known to be secreted by neutrophils, in CRS was also expressed in eosinophils. In addition, calprotectin, which functions as an antimicrobial peptide, may play an important role in the innate immune response based on its EETs involvement. Therefore, calprotectin expression could reflect as a disease severity biomarker for CRS.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - March 18, 2023 Category: Allergy & Immunology Authors: Sang Hyeon Ahn, Kyu Ha Shin, Jun Taek Oh, Sang Chul Park, Min ‐Seok Rha, Soo In Kim BS, Hyung‐Ju Cho, Joo‐Heon Yoon, Chang‐Hoon Kim Tags: ORIGINAL ARTICLE Source Type: research

Usefulness of the JESREC scoring system in assessing asthma patients with eosinophilic chronic rhinosinusitis
In this study, we assessed the usefulness of this system in evaluating asthma patients with ECRS.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Shingo Takahashi, Toshihiro Shirai, Taisuke Akamatsu, Aya Matsubara Source Type: research

The Percentage of PNAd-Expressing Vessels is Correlated with Disease Severity in Eosinophilic Chronic Rhinosinusitis
CONCLUSION: These results strongly suggest that PNAd-expressing vessels play at least a partial role in eosinophil recruitment to nasal polyps and consequent severity of ECRS.PMID:36172642 | DOI:10.1177/19458924221129903
Source: American Journal of Rhinology and Allergy - September 29, 2022 Category: ENT & OMF Authors: Eiichi Kato Toshiki Tsutsumiuchi Akifumi Muramoto Takahiro Tokunaga Shigeharu Fujieda Motohiro Kobayashi Source Type: research

Inflammatory molecular endotypes of nasal polyps derived from White and Japanese populations
Emerging evidence suggests that chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly heterogeneous disease with disparate inflammatory characteristics between different racial groups and geographies. Currently, little is known about possible underlying distinguishing factors between these inflammatory differences.
Source: Journal of Allergy and Clinical Immunology - December 1, 2021 Category: Allergy & Immunology Authors: Tsuguhisa Nakayama, Ivan T. Lee, Wei Le, Yasuhiro Tsunemi, Nicole A. Borchard, David Zarabanda, Sachi S. Dholakia, Philip A. Gall, Angela Yang, Dayoung Kim, Makoto Akutsu, Takashi Kashiwagi, Zara M. Patel, Peter H. Hwang, Daniel N. Frank, Shin-ichi Haruna Source Type: research

Inflammatory molecular endotypes of nasal polyps derived from Caucasian and Japanese populations
Emerging evidence suggests that chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly heterogeneous disease with disparate inflammatory characteristics between different racial groups and geographies. Little is known currently about possible distinguishing factors underlying these inflammatory differences.
Source: Journal of Allergy and Clinical Immunology - December 1, 2021 Category: Allergy & Immunology Authors: Tsuguhisa Nakayama, Ivan T. Lee, Wei Le, Yasuhiro Tsunemi, Nicole A. Borchard, David Zarabanda, Sachi S. Dholakia, Philip A. Gall, Angela Yang, Dayoung Kim, Makoto Akutsu, Takashi Kashiwagi, Zara M. Patel, Peter H. Hwang, Daniel N. Frank, Shin-ichi Haruna Source Type: research

Regulation of the Expression of SARS-CoV-2 Receptor Angiotensin-Converting Enzyme 2 in Nasal Mucosa
CONCLUSION: Inflammatory endotype affects ACE2 expression in the nasal mucosa and influences susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In particular, type 2 inflammation could downregulate ACE2 expression in the nasal mucosa and reduces susceptibility to SARS-CoV-2 in patients with CRSwNP. Although in vivo experiments are required, administration of SCFAs to the nasal cavity might be worthy of consideration as a preventative or therapeutic strategy for the early-stage COVID-19.PMID:34232770 | DOI:10.1177/19458924211027798
Source: American Journal of Rhinology and Allergy - July 7, 2021 Category: ENT & OMF Authors: Tetsuji Takabayashi Kanako Yoshida Yoshimasa Imoto Robert P Schleimer Shigeharu Fujieda Source Type: research

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis
CONCLUSION: Although benralizumab did not meet the primary efficacy endpoint, reductions of nasal polyp scores were seen in the benralizumab group compared with the placebo group over the whole study period, especially in patients with high levels of blood eosinophils.PMID:33840229 | DOI:10.1177/19458924211009429
Source: American Journal of Rhinology and Allergy - April 12, 2021 Category: ENT & OMF Authors: Tetsuji Takabayashi Daiya Asaka Yoshitaka Okamoto Tetsuo Himi Shinichi Haruna Naohiro Yoshida Kenji Kondo Mamoru Yoshikawa Yasunori Sakuma Kunihiko Shibata Motohiko Suzuki Masayoshi Kobayashi Ryo Kawata Kenzo Tsuzuki Mitsuhiro Okano Takaya Higaki Sachio T Source Type: research

Pages: 1  2